RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II

Recruiting

99 years or below

All

Phase 2

5 participants needed

1 Location

Brief description of study

This is a Phase II single-arm, single-site, open label clinical trial with r/r HL patients, aimed to determine whether a RadVax approach using low-dose RT added to nivolumab can improve response among patients who do not achieve a CR to nivolumab alone. The long-term goal is to develop an effective regimen for r/r HL patients.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: ['Hodgkin Lymphoma']
Age: 99 years or below
Gender: All

Updated on 19 Feb 2024. Study ID: 828966

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

Brief description of study

Eligibility of study

Find a site